SEC Form 4 · accession 0001677455-26-000002
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karah Herdman Parschauer
Officer — EVP and Chief Legal Officer
Period of report
Jun 15, 2026
Accepted (ET)
Jun 15, 2026 · 6:46 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 15, 2026 | S | 1,899 | $24.62 | D | 94,462 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 646 shares acquired under the Company's Amended and Restated Employee Stock Purchase Place on April 30, 2026
- F2Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.